

faculty

Roberto Bei, Rome
Carmen Belli, Milan
Francesco Brancati, L'Aquila
Davide Brocco, Chieti
Michelangelo Campanella, London
Mattia Capulli, L'Aquila
Michele Carbone, Hawaii, US
Annamaria Cimini, L'Aquila
Pasquale Cioffi, L'Aquila
Carlo Maria Croce, Columbus, US
Simona Delle Monache, L'Aquila
Dulio Divisi, Teramo

Nicola D'Ostilio, Vasto
Edoardo Francini, Florence
Carlo Ganini, Bari
Giovanni Luca Gravina, L'Aquila
Steven Gray, Dublin, IE
Stefano Landi, Pisa
Esther Liberatore, L'Aquila
Maria Angela Licata, L'Aquila
Mauro Maccarrone, L'Aquila
Andrew Reay Mackay, L'Aquila
Olga Martelli, Rome
Sarah Masato, Rome
Francesco Masedu, L'Aquila
Gerry Melino, Rome

Filippo Mignosi, L'Aquila
Laura Moro, Novara
Luciano Mutti, L'Aquila
Giuseppe Novelli, Rome
Stefania Oliveto, Milan
Cristina Pellegrini, L'Aquila
Luigi Pirtoli, Florence
Daniele Ricci, L'Aquila
Tina Sidoni, L'Aquila
Pierosandro Tagliaferri, Catanzaro
Nicola Tinari, Chieti
Marianna Tudini, L'Aquila
Lucilla Verna, L'Aquila

PATRONAGES - UNDER THE AUSPICES OF

Con l'Alto Patronato
della Regione Abruzzo



UNIVERSITÀ
DEGLI STUDI
DELL'AQUILA



3rd meeting

on cutting edge advancements
in our fight against cancer
science as a symbol of resilience
of a town and a community

Scientific Director

Prof. Luciano Mutti

21st-22nd November 2025

Sala Ipogea

Consiglio Regionale dell'Abruzzo

Via Michele Iacobucci, 4,
L'Aquila

WITH THE UNCONDITIONED SUPPORT OF

AMGEN



NOVARTIS



REGENERON
SCIENCE TO MEDICINE



SCIENTIFIC DIRECTOR

Prof. Luciano Mutti

Professor of Medical Oncology, University of L'Aquila

Director of Oncology Unit, San Salvatore Hospital, ASL1 Abruzzo, Avezzano - Sulmona - L'Aquila

SCIENTIFIC SECRETARIAT

Dr. Paola Lanfiuti Baldi, Dr. Valentina Cocciolone, Dr. Raffaella Losito, Dr. Tiziana Trapasso, Dr. Lucilla Verna

CME ID-EVENT: 1023 - 460814

CME accreditation for: Medical Doctor, Pharmacist, Biologist, Nurse, Biomedical Laboratory Technician, Medical Radiation Technologist. Educational event duration: 11 hours. CME-Credits n. 11.

Educational objective: Clinical documentation. Clinic, assistance, diagnostic and rehabilitative pathways, care and assistance profiles (3). Italian CME credits will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality and duly fill in the evaluation questionnaires answering correctly 75% of the questions.

REGISTRATION

Registration is free of charge: www.events-communication.com/event/cuttingedgeadv2025

For information: segreteria4@events-communication.com

SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER



Events srl
Via Lorenzo Lotto 9, 60019 Senigallia (AN)
Via Sabotino 14, 20135 Milano (MI)
www.events-communication.com



overview

This third meeting will be held on 21/22 November 2025 in L' Aquila and will represent our sustained efforts to attract bright minds, ideas and projects.

Therefore the aim of the meeting will be gathering a group of world-class scientists that thanks to lectures and open audience panels will offer a unique opportunity of presentation of high quality science along with creating a chance of fruitful networking.

“Trail-blazing” is the word for future of cancer research should be imbued with to inform the clinical community and improve cancer prognosis.

Therefore, on this premise, all the meeting is designed for leaving the floor to game-changer preclinical and clinical scientists showing how the integration of these two approaches can be of mutual benefit for cancer patients

The topics are of particular interest to MD (Medical Doctor), preclinical and clinical scientists.

SCIENTIFIC PROGRAM

21st November

09.00 Registration opens

09.20 Greetings **L. Mutti**

A YEAR LATER: what's new? A glimpse at current precision oncology

Moderators: **N. D'Ostilio, P.S. Tagliaferri, N. Tinari**

09.30 Lung Cancer: advances in targeted therapy for CNS metastatic NSCLC
D. Brocco

09.45 Genito-Urinary Cancer: PARPi on castration resistant prostate cancer and advanced RCC myths and reality
E. Francini

10.00 Molecular testing in advanced melanoma: state of the art and heads up
C. Pellegrini

10.30 Audience panel/ discussion
D. Divisi, M.A. Licata

11.00 Coffee Break

A tsunami Called A.I.

Moderators: **M. Capulli, F. Mignosi, G. Novelli**

11.15 Genetics, precision medicine and biobanking: the tools of community resilience in the fight against cancer
G. Novelli

11.30 A.I in clinical oncology: the onco-rheumatology model
L. Pirtoli

11.45 A.I. and biomedical research
F. Mignosi

12.00 Audience Panel/ discussion
M. Capulli, F. Mignosi, G. Novelli, L. Pirtoli

12.30 Lunch

Pitfalls and future impact of targeted therapies

1st PART

Moderators: **A. Mackay, C. Ganini**

13.30 Do CDK4/CDK6 inhibitors benefit breast cancer patients?

L. Verna

13.45 Kras is a new actionable target: heads up
C. Belli

14.00 What future for TKI-targeted treatment
R. Bei

14.15 Audience panel/ discussion
C. Belli, T. Sidoni, L. Verna

From environment to genetics

Moderators: **A. Cimini, G. Melino, G. Novelli**

Spotlight Speaker:

14.45 Role of IcosL in tumor rejection
C. Croce

Pitfalls and future impact of targeted therapies

2nd PART

Moderators: **A. Cimini, G.L. Gravina**

15.15 Breast Cancer: combined therapies in the adjuvant and neo-adjuvant settings: impact of subcutaneous anti-HER2+ formulation

T. Sidoni

16.00 Spotlight on advanced renal cell Carcinoma
C. Ganini

16.15 The survival of endometrial cancer: an update
O. Martelli

16.30 Hormonal manipulation for early and advanced prostate cancer: what's new?
M. Tudini

16.45 Audience panel/ discussion
A. Cimini, C. Ganini, G.L. Gravina, O. Martelli, T. Sidoni, M. Tudini

17.00 The financial burden of the new cancer drugs: are they worth the cost?
Chaired and Presented by
P. Cioffi, S. Gray, E. Liberatore, S. Masato, F. Masedu, D. Ricci

22nd November

Cancer Biology Facts and Fads: where are we at?

Moderators: **F. Brancati, A. Cimini**

09.00 Liquid biopsies in pleural mesothelioma

S. Landi

09.20 Senescence and pleural mesothelioma: exploiting roles and therapeutic opportunities
L. Moro

09.40 New strategies of immunotherapies for human tumors
S. Oliveto

10.00 Single cells analysis and mass cytometry
S. Oliveto

10.20 Hypoxic cancer and immune response
S. Gray

10.40 Tumour cells mitochondria as a target for treatment: a year later
M. Campanella

11.00 New advances in resolution of inflammation
M. Maccarrone

11.20 Audience panel/ discussion
S. Delle Monache, L. Moro, L. Mutti

From Environment to Genetics

Moderators: **A. Cimini, G. Melino, G. Novelli**

Spotlight Speakers:

11.40 Mesothelioma in carriers of germline BAP1 mutations: a different disease biologically, histologically and clinically, that for the most part does not require aggressive therapies and that is compatible with a long life span
M. Carbone

12.10 Conclusions
L. Mutti

12.30 Lunch